Yao Strategy for the Treatment of de Novo Medina 0,1,0 or 0,0,1 Bifurcation Lesion

NCT ID: NCT06166459

Last Updated: 2024-03-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-22
• Study Completion Date: 2026-03-01

Brief Summary

Percutaneous coronary intervention for coronary bifurcation lesions represents one of the most challenging procedures in interventional cardiology because of lower angiographic success rate and increased risk of procedural complications. The study is designed to enroll 200 patients with acute or chronic coronary syndromes that meet the indications for intervention and with angiographic confirmed de novo Medina type 0,1,0 or 0,0,1 bifurcation lesion. In view of the potential risks of using DCB alone in the treatment of de novo bifurcation lesions, the following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy). The primary endpoint was late lumen loss and major adverse cardiovascular events.

Conditions

Coronary Artery Disease; Bifurcation Lesion

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Yao technique

The following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy).

Group Type: EXPERIMENTAL

Drug-coated balloon combined with provisional drug-eluting stent implantation

Intervention Type: PROCEDURE

(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).

Interventions

Drug-coated balloon combined with provisional drug-eluting stent implantation

(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Subjects at the age between ≥18 and ≤80 years old;

2. De novo native lesion, Median type 010/001 bifurcation lesion;

3. The reference diameter of the target vessel was 2.75-4.0mm and the length was less than 40mm;

4. Subjects are willing to participate in the study, sign informed consent form, and accept clinical follow-up.

Exclusion Criteria

1. The diameter stenosis of adjacent branch vessel ostium ≥50%;

2. Acute ST-segment elevation myocardial infarction;

3. Stents implanted within 10 mm proximal or distal to the target lesion;

4. Aneurysm within 10 mm proximal or distal to the target lesion;

5. There is target vessel distortion or severe calcification lesion, so balloon catheter fails to pass;

6. Previous coronary artery bypass grafting;

7. Evidence for extensive thrombus within target vessel;

8. Evidence of heart failure by at least one of the following: a. Most recent LVEF ≤35%, or b. Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or c. Killip class ≥2 (post STEMI patients);

9. Subjects with a life expectancy of ≤1 year;

10. Subjects with stroke, peptic ulcer, or gastrointestinal bleeding within the past 6 months;

11. Subjects with severe renal failure (eGFR<30ml/minute), failure to comply with angiography conditions;

12. Subjects who are intolerance to aspirin and/or clopidogrel or ticagrelor or have contraindications;

13. Subjects who are intolerance or allergic to heparin, contrast agent;

14. Patients who are participating in the clinical trial of other drug or device without reaching the time limit of primary endpoint;

15. Subjects who are not applicable to be enrolled by investigators due to other reasons.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xuzhou Third People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yaojun Zhang, Dr

Role: STUDY_CHAIR

Xuzhou Third People's Hospital

Central Contacts

Yaojun Zhang, Dr

Role: CONTACT

13770668667@139.com

+86-13770668667

References

Escarcega RO. What is the Optimal Technique for Ostial Left Anterior Descending Artery Lesions? Cardiovasc Revasc Med. 2019 Dec;20(12):1063-1064. doi: 10.1016/j.carrev.2019.10.003. Epub 2019 Oct 22. No abstract available.

Reference Type: BACKGROUND

PMID: 31669112 (View on PubMed)

Dishmon DA, Elhaddi A, Packard K, Gupta V, Fischell TA. High incidence of inaccurate stent placement in the treatment of coronary aorto-ostial disease. J Invasive Cardiol. 2011 Aug;23(8):322-6.

Reference Type: BACKGROUND

PMID: 21828393 (View on PubMed)

Hildick-Smith DJ, Shapiro LM. Ostial left anterior descending coronary artery stent positioning: partial preinflation prevents stent oscillation and facilitates accurate deployment. J Interv Cardiol. 2001 Aug;14(4):439-42. doi: 10.1111/j.1540-8183.2001.tb00355.x.

Reference Type: BACKGROUND

PMID: 12053499 (View on PubMed)

Cayli M, Elbasan Z, Gur M, Seker T, Ucar H, Kuloglu O, Sen O, Sahin DY, Kalkan GY. Modified flower petal technique in the treatment of Medina type 0,0,1 or 0,1,0 lesions. EuroIntervention. 2015 Nov;11(7):772-9. doi: 10.4244/EIJV11I7A154.

Reference Type: BACKGROUND

PMID: 26603986 (View on PubMed)

Gutierrez-Chico JL, Villanueva-Benito I, Villanueva-Montoto L, Vazquez-Fernandez S, Kleinecke C, Gielen S, Iniguez-Romo A. Szabo technique versus conventional angiographic placement in bifurcations 010-001 of Medina and in aorto-ostial stenting: angiographic and procedural results. EuroIntervention. 2010 Feb;5(7):801-8. doi: 10.4244/eijv5i7a134.

Reference Type: BACKGROUND

PMID: 20142194 (View on PubMed)

Chen GC, Lu XM, Song YM, Gyawail L, Geng ZH, Song MB, Qian DH, Zhang YP, Ni DC, He Y. A 3-year experience of a simple, novel technique for accurate ostial/non-ostial coronary stenting: The buddy balloon anchor stent technique. Catheter Cardiovasc Interv. 2018 Nov 15;92(6):1147-1152. doi: 10.1002/ccd.27667. Epub 2018 Jul 18.

Reference Type: BACKGROUND

PMID: 30019847 (View on PubMed)

Yang ZK, Hu J, Ding FH, Ni JW, Zhang RY, Shen WF. One-year outcome of single-stent crossover versus accurate ostial stenting for isolated left anterior descending ostial stenosis. Coron Artery Dis. 2022 Jan 1;31(1):e67-e72. doi: 10.1097/MCA.0000000000001071.

Reference Type: BACKGROUND

PMID: 34010192 (View on PubMed)

Elkhateeb O, Thambi S, Beydoun H, Bishop H, Quraishi A, Kidwai B, Title L. Long-term outcomes following ostial left anterior descending artery intervention with or without crossover to left-main. Am J Cardiovasc Dis. 2022 Apr 15;12(2):73-80. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35600287 (View on PubMed)

Vaquerizo B, Fernandez-Nofreiras E, Oategui I, Suarez de Lezo J, Rumoroso JR, Martin P, Routledge H, Tizon-Marcos H. Second-Generation Drug-Eluting Balloon for Ostial Side Branch Lesions (001-Bifurcations): Mid-Term Clinical and Angiographic Results. J Interv Cardiol. 2016 Jun;29(3):285-92. doi: 10.1111/joic.12292.

Reference Type: BACKGROUND

PMID: 27245124 (View on PubMed)

Erdogan E, Li Z, Zhu YX, Tufaro V, Feng SL, Li Q, Liang L, Chang S, Bu LT, Liu B, Zhou QH, Yap NAL, Bourantas CV, Zhang YJ. DCB combined with provisional DES implantation in the treatment of De Novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study. Anatol J Cardiol. 2022 Mar;26(3):218-225. doi: 10.5152/AnatolJCardiol.2021.1157.

Reference Type: BACKGROUND

PMID: 35346908 (View on PubMed)

Other Identifiers

2023-02-022-K01

Identifier Type: -

Identifier Source: org_study_id